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Objective: To study whether miR-21 targets and inhibits tumor suppressor gene PTEN
can promote prostate cancer cell proliferation and invasion.
Methods: Prostate cancer cell lines PC-3 were cultured and divided into negative control
group (NC group), miR-21 group, pcDNA3.1 group, miR-21+pcDNA3.1 group and miR-
21+PTEN group that were transfected with different miR and plasmid, respectively. After
12 h and 24 h of transfection, the cell viability and invasive cell number were determined;
after 24 h of transfection, Bcl-2, Survivin, MMP2, MMP9, PTEN, PI3K, and AKT
expression in cells were determined.
Results: After 12 h and 24 h of transfection, OD value and invasive cell number of miR-
21 group were signiﬁcantly higher than those of NC group; after 24 h of transfection, Bcl-
2, Survivin, MMP2, MMP9, PI3K and AKT expression levels were signiﬁcantly higher
than those of NC group while PTEN expression level was signiﬁcantly lower than that of
NC group; after 12 h and 24 h of transfection, OD value and invasive cell number of miR-
21+pcDNA3.1 group were signiﬁcantly higher than those of pcDNA3.1 group, and the
OD value and invasive cell number of miR-21+PTEN group were signiﬁcantly lower than
those of miR-21+pcDNA3.1 group; after 24 h of transfection, Bcl-2, Survivin, MMP2 and
MMP9 content of miR-21+pcDNA3.1 group were signiﬁcantly higher than those of
pcDNA3.1 group, and Bcl-2, Survivin, MMP2 and MMP9 content of miR-21+PTEN
group were signiﬁcantly lower than those of miR-21+pcDNA3.1 group.
Conclusions: miR-21 can target and inhibit tumor suppressor gene PTEN expression to
promote prostate cancer cell proliferation and invasion.1. Introduction
Prostate cancer is a common malignant tumor of male urinary
system, its incidence is rising year by year, and the common
clinical treatments include surgical resection, radiotherapy and
chemotherapy as well as castration [1–3]. Cell proliferation and
invasion are the most prominent biological features ofprostate cancer, but the regulatory mechanism of prostate
cancer cell proliferation and invasion is not very clear, and
the corresponding clinical targeted drugs are also short.
MicroRNA (miR) is a class of small non-coding RNAs
discovered in recent years, which adjusts the expression of a
variety of genes to inﬂuence the biological behaviors of cells.
miR-21 is a miRNA widely studied in malignant tumors, which
shows high expression in cervical cancer, colorectal cancer,
breast cancer and other malignant tumors, has the characteristics
of proto-oncogene and can promote the cancer cell proliferation
and invasion [4–6]. Domestic cytological study by Xiao Li [7]
shows that miR-21 can target and inhibit the expression of tu-
mor suppressor gene PTEN so as to weaken pro-apoptotic ef-
fects mediated by PTEN. However, it is not clear whether miR-
21 can control the prostate cancer proliferation and invasion by
PTEN. The following study aimed to conﬁrm whether miR-21
targeted and inhibited PTEN to promote prostate cancer cell
proliferation and invasion.nder the CC BY-NC-ND license (http://
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2.1. Research materials
Prostate cancer cell lines PC-3 were bought from the cell
bank of Chinese Academy of Sciences, the RPMI1640 medium
and fetal bovine serum for cell culture as well as the trypsin for
cell digestion were purchased from Gibco Company, miR-21
analogs were synthesized by Shanghai Genepharma Company,
pcDNA3.1(+) plasmid containing PTEN coding sequence were
built by Shanghai Jerry Company, and transfection reagents
Lipofectamine™2000 were purchased from Invitrogen Com-
pany. Cell viability detection kits were bought from Promega
Company, and enzyme-linked immunosorbent assay kits were
purchased from Shanghai Westang Biotechnology Company.
2.2. Experimental methods
2.2.1. Cell culture methods
PC-3 cell lines were recovered and then cultured with
RPMI1640 culture medium containing 10% fetal bovine serum,
the cell culture medium was replaced every 2 d, the status of cell
growth was observed, the cells were digested with 0.25% trypsin
after the cell density reached 80–90%, then centrifuged,
collected and re-suspended, some cells were inoculated in the
culture bottle and continued to be digested, digested and sub-
cultured, and some cells were inoculated in the cell culture
plate for treatment.
2.2.2. Cell grouping and treatment methods
According to the different treatment conditions, the cells
were divided into negative control group (NC group), miR-21
group, pcDNA3.1 group, miR-21+pcDNA3.1 group and miR-
21+PTEN group, and Lipofectamine™2000 instructions were
followed for miRNA sequence and plasmid transfection. NC
group were only transfected with negative control miRNA se-
quences, miR-21 group were transfected with miR-21 se-
quences, pcDNA3.1 group were transfected with pcDNA3.1
blank plasmids, miR-21+pcDNA3.1 group were transfected with
pcDNA3.1 blank plasmids and miR-21 sequences, and miR-
21+PTEN group were transfected with pcDNA3.1 plasmid
containing PTEN coding sequences as well as miR-21
sequences.
2.2.3. Cell viability detection methods
The cells for cell viability detection were inoculated in 96-
well plate, 20 mL cell viability detection ﬂuid was added in
each wells after miRNA sequence and plasmid transfection for
12 h and 24 h, cells continued to be incubated for four hours in
the incubator, shaken and mixed, then the cell plate was placed
on microplate reader to measure the absorbance value (OD
value) at 450 nm wavelength, and the OD value was used to
reﬂect the cell viability.
2.2.4. Cell invasion detection methods
The cells for cell invasion detection were inoculated in
Transwell Chambers, the Transwell Chambers were taken out
after miRNA sequence and plasmid transfection for 12 h and
24 h, the ﬁlter membrane at the bottom of chambers was taken
down and stained with crystal violet, and then the number of
cells within 3 random ﬁelds was observed under the microscope.2.2.5. Protein content detection methods
The cells for protein content detection were inoculated in 6-
well plate and transfected with miRNA sequences and plasmids
for 24 h, the culture medium was abandoned and the cells were
kept and washed with PBS buffer for 2–3 times, then 120 mL
protein lysis buffer was added in the culture wells, the cells were
fully broken and then centrifuged, the residue was abandoned
and the supernatant was kept, enzyme-linked immunosorbent
assay kits were used to determine the Bcl-2, Survivin, MMP2,
MMP9, PTEN, PI3K and AKT content in the supernatant.
2.3. Statistical analysis
SPSS20.0 software was used to input and analyze data, mea-
surement data analysis between two groups was by t test, mea-
surement data analysis among groups was by variance analysis
and P < 0.05 indicated statistical signiﬁcance in differences.
3. Results
3.1. Regulatory effect of miR-21 analog transfection on
cell proliferation activity and invasion ability
Analysis of cell viability OD value and invasive cell number
between NC group and miR-21 group was as follows: after 12 h
and 24 h of transfection, OD value and invasive cell number of
miR-21 group were signiﬁcantly higher than those of NC group.
Differences in OD value and invasive cell number were statis-
tically signiﬁcant between NC group and miR-21 group.
3.2. Regulatory effect of miR-21 analog transfection on
cell proliferation- and invasion-related gene expression
Analysis of the proliferation-related genes Bcl-2 and Survivin
as well as the invasion-related genes MMP2 and MMP9 expres-
sion between NC group and miR-21 group was as follows: after
24 h of transfection, Bcl-2, Survivin, MMP2 and MMP9 content
of miR-21 were signiﬁcantly higher than those of NC group.
Differences in Bcl-2, Survivin, MMP2 and MMP9 content were
statistically signiﬁcant between NC group and miR-21 group.
3.3. Regulatory effect of miR-21 analog transfection on
PTEN and its downstream signaling molecule
expression
Analysis of PTEN and its downstream signaling molecules
PI3K and AKT expression between NC group and miR-21 group
was as follows: after 24 h of transfection, PTEN content of miR-
21 group was signiﬁcantly lower than that of NC group while
PI3K andAKT content were signiﬁcantly higher than those of NC
group. Differences in PTEN, PI3K and AKT content were sta-
tistically signiﬁcant between NC group and miR-21 group.
3.4. Regulatory effect of miR-21 analog and PTEN-
overexpression plasmid transfection on cell
proliferation and invasion
Analysis of cell viability OD value and invasive cell number
after miR-21 analog and PTEN-overexpression plasmid trans-
fection was shown in Table 1: after 12 h and 24 h of transfection,
OD value and invasive cell number of miR-21+pcDNA3.1
Table 1
Cell proliferation activity, invasion ability, proliferation- and vasion-related gene expression, PTEN and its downstream signaling molecule expre ion of NC group and miR-21 group.
Groups Repeated batches Cell viability OD valu Invasive cell number Proliferation genes (ng/mL) Invasion genes ( /mL) PTEN (ng/mL) PI3K (pg/mL) AKT (pg/mL)
12 h 24 h 12 h 24 h Bcl-2 Survivin MMP9 MP2
NC group 5 0.67 ± 0.09 0.78 ± 0 14.42 ± 1.85 18.35 ± 2.15 6.48 ± 0.93 4.76 ± 0.55 113.42 ± 15.58 92 1 ± 10.34 10.32 ± 1.45 77.65 ± 9.34 113.42 ± 16.58
miR-21 group 5 0.94 ± 0.11 1.25 ± 0 20.39 ± 2.77 31.26 ± 4.48 9.42 ± 1.14 8.97 ± 0.93 189.34 ± 22.38 157 4 ± 16.78 4.62 ± 0.65 125.42 ± 14.58 187.87 ± 22.38
T 7.182 6.684 7.615 7.932 7.029 9.652 8.327 .758 12.482 8.947 9.571
Table 2
Cell proliferation activity, invasion ability, proliferation- an vasion-related gene expression after miR-21 analog and PTEN-overexpression plas id transfection.
Groups Repeated batches l viability OD value Invasive cell number Proliferatio genes (ng/mL) Invasion genes (pg/mL)
h 24 h 12 h 24 h Bcl-2 Survivin MMP2 MMP9
pcDNA3.1 group 5 0.62 0.08 0.73 ± 0.09 12.67 ± 1.68 16.78 ± 2.24 6.03 ± 0.67 4.25 ± 0.58 88.94 ± 11.38 105.56 ± 12.58
miR-21+pcDNA3.1 group 5 1.17 0.22* 1.39 ± 0.23* 18.95 ± 2.48* 24.15 ± 3.41* 9.77 ± 1.07* 9.14 ± 1.18* 167.31 ± 19.34* 197.33 ± 25.62*
miR-21+PTEN group 0.88 0.10△ 0.94 ± 0.12△ 14.52 ± 1.67△ 19.87 ± 2.33△ 7.86 ± 0.80△ 5.89 ± 0.74△ 113.24 ± 13.48△ 135.42 ± 16.70△
F 8 8.491 6.537 7.757 6.938 9.282 9.681 8.658
*Compared with pcDNA3.1 group, P＜0.05.
△Compared with miR-21+pcDNA3.1 group, P＜0.05.
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and the OD value and invasive cell number of miR-21+PTEN
group were signiﬁcantly lower than those of miR-
21+pcDNA3.1 group. Analysis of proliferation- and invasion-
related gene expression in cells was shown in Table 2: after
24 h of transfection, Bcl-2, Survivin, MMP2 and MMP9 content
of miR-21+pcDNA3.1 group were signiﬁcantly higher than
those of pcDNA3.1 group, and Bcl-2, Survivin, MMP2 and
MMP9 content of miR-21+PTEN group were signiﬁcantly lower
than those of miR-21+pcDNA3.1 group.
4. Discussion
MicroRNA (miR) is a class of non-coding small RNAs with
extensive biological effects, and a number of basic researches
have conﬁrmed that miR-21 has characteristics of proto-oncogene
and plays a signiﬁcant role in promoting cancer cell growth,
proliferation and invasion [8,9]. Prostate cancer is a common
malignant tumor of the male reproductive system, the incidence
increases year by year, but the mechanism is still not clear [10].
Cell study of domestic Xiao Li [7] shows that miR-21 shows the
trend of high expression in prostate cancer tissues andmiR-21 can
target and inhibit the expression of tumor suppressor gene PTEN
in prostate cancer cells; the study of Yang B shows that the highly
expressed miR-21 has certain value for the prognosis of prostate
cancer [11]. The above study results indicate that miR-21 has
shown the characteristics of proto-oncogene in the occurrence and
development process of prostate cancer, and has a promoting ef-
fect on the occurrence and development of tumor. So it was
speculated that miR-21 played an important role in regulating
prostate cancer proliferation, invasion and other processes. To test
this theory, miR-21 analog was transfected into prostate cancer
cells, the cell viability, invasive cell number and related gene
expression were analyzed in the study, and the results showed that
miR-21 analog transfection can increase the prostate cancer cell
viability, increase the invasive cell number and up-regulate the
expression of anti-apoptotic genes Bcl-2 and Survivin as well as
pro-proliferation genes MMP2 and MMP9. This means that miR-
21 plays a signiﬁcant role in promoting prostate cancer prolifer-
ation and invasion.
In recent years, the speciﬁc ways for miRNA to exert
biological effects have received more and more attention, there
are rich miRNA binding sites in the miRNA-regulated target gene
mRNA 30 non-coding region (30UTR), miRNA can be combined
with the corresponding target gene mRNA 30UTR and
then induce the corresponding mRNA degradation or inhibit
the corresponding mRNA transcription, which is ﬁnally
characterized by the decrease of corresponding target gene
expression [12–15]. In the study, miR-21 was highly expressed in
prostate cancer tissue, the genes under the targeted regulation of
miR-21 should show the trend of low expression, and miR-21
analog should be able to inhibit the expression of corresponding
target genes in prostate cancer cells. However, it was observed
after miR-21 analog transfection that the expression of anti-
apoptotic genes Bcl-2 and Survivin as well as pro-proliferation
genes MMP2 and MMP9 signiﬁcantly increased. Thus it
indicates that miR-21 does not directly target the Bcl-2 and
Survivin as well as MMP2 and MMP9, and its possible way of
action is to target and adjust tumor suppressor gene and decrease
tumor suppressor gene expression so as to enhance the malignant
biological behaviors of cancer cells and promote the expression of
malignant molecules.Phosphatase and tensin homolog deleted on chromosome ten
(PTEN) is now known as a relatively clear tumor suppressor
gene, and the encoded protein has both lipid phosphatase and
protein phosphatase activity, and can make the PI3K 3-
phosphorylation sites in cells dephosphorylate and inhibit
downstream signaling molecule Akt phosphorylation. When the
expression of PTEN gene in cells is reduced or deleted, the
dephosphorylation effect on PI3K/Akt signaling pathway is
weakened, the function is correspondingly enhanced and it
promotes cell proliferation and invasion [16,17]. Studies have
shown that the expression of PTEN decreases signiﬁcantly in
prostate tissue and is closely related to the TNM staging of
the tumor [18,19], and in the experiments in vitro of breast
cancer, colorectal cancer and other malignant tumor cells, the
researchers have found that miR-21 has targeted inhibition ef-
fect on the expression of PTEN [19,20]. In the study, the PTEN/
PI3K/Akt expression in prostate cancer cells was analyzed after
miR-21 analog transfection, and the results showed that PTEN
content of miR-21 group was signiﬁcantly lower than that of NC
group while PI3K and AKT content were signiﬁcantly higher
than those of NC group. This means that miR-21 can target and
inhibit the expression of tumor suppressor gene PTEN and
enhance the function of the downstream signaling pathways
PI3K/Akt in prostate cancer cells.
After conﬁrming the regulatory effect of miR-21 on prostate
cancer proliferation and invasion as well as PTEN expression,
and in order to further clarify whether miR-21 directly regulated
the expression of PTEN to inﬂuence the proliferation and in-
vasion of prostate cancer cells, PTEN-overexpression plasmid
and miR-21 analog were both transfected into prostate cancer
cells, and the cell viability, the invasive cell number and the
related gene expression were analyzed. The analysis results
showed that miR-21 and blank plasmid transfection could
signiﬁcantly increase the cell viability, the invasive cell number
as well as the Bcl-2, Survivin, MMP2 and MMP9 expression,
and transfection of both miR-21 and PTEN-overexpression
plasmid could reverse the miR-21 effects on cell viability and
cell invasion, which was characterized that the OD value,
invasive cell number as well as Bcl-2, Survivin, MMP2 and
MMP9 expression of miR-21+PTEN group were signiﬁcantly
lower than those of miR-21+pcDNA3.1 group. It illustrates that
the promoting effect of miR-21 on prostate cancer cell prolif-
eration and invasion is realized by targeting inhibition of the
expression of PTEN.
In conclusion, miR-21 can target and inhibit tumor sup-
pressor gene PTEN expression to promote prostate cancer cell
proliferation and invasion.
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